February 2012 Drug Update Information - Pharmacy Benefits ...

More documents

Recommendations

Info

10 mg tablets, 100 count (NDC 00406-1122- -01) 10 mg tablets, 1000 count (NDC 00406-1122-10) 20 mg tablets, 100 count (NDC 00406-1124- -01) 20 mg tablets, 1000 count (NDC 00406-1124-10) Ritalin, Novartis 5 mg tablets, 100 count (NDC 00078-0439-05) Methylphenidate, Sandoz 5 mg tablets, 100 count (NDC 00781-5748-01) 10 mg tablets, 100 count (NDC 00781-5749- -01) 20 mg tablets, 100 count (NDC 00781-5753- -01) Methylphenidate, Watson 5 mg tablets, 100 count (NDC 00591-5882-01) 10 mg tablets, 100 count (NDC 00591-5883- -01) 20 mg tablets, 100 count (NDC 00591-5884- -01) Methylphenidate, UCB 5 mg tablets, 100 count (NDC 53014-0531-07) 10 mg tablets, 100 count (NDC 53014-0530- -07) 20 mg tablets, 100 count (NDC 53014-0532- -07) Reason for the Shortage Novartis and UCB cannot provide a reason for the shortage. Mallinckrodt states the shortage is due to delay in the release of theirr DEA quota. Sandoz states that the shortage is due to delay in obtaining raw materials. JOM could not provide a reason for the shortage. Watson states the shortage is due to increased demand for their products. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=752 Source: http://www.a ashp.org Labetalol Tablets January 30, 2012 Products Affected - Description Labetalol tablets, Major 200 mg, 100 count (NDC 00904-5929-61) Labetalol tablets, Sandoz 100 mg, 100 count (NDC 00185-0010-01) 100 mg, 500 count (NDC 00185-0010-05) 200 mg, 100 count (NDC 00185-0117-01) 200 mg, 500 count (NDC 00185-0117-05) 300 mg, 100 count (NDC 00185-0118-01) 300 mg, 500 count (NDC 00185-0118-05) Labetalol tablets, Teva 100 mg, 100 count, unit dose (NDC 00172-4364-10) 100 mg, 500 count (NDC 00172-4364-70) 200 mg, 100 count, unit dose (NDC 00172-4365-10) Labetalol tablets, UDL 200 mg, 100 count, unit dose (NDC 51079-0929-20) Labetalol tablets, Watson 100 mg, 100 count (NDC 00591-0605-01) 200 mg, 100 count (NDC 00591-0606-01) 200 mg, 500 count (NDC 00591-0606-05) 300 mg, 100 count (NDC 00591-0607-01) 40
Trandate tablets, Prometheus 100 mg, 100 count (NDC 65483-0391-10) 200 mg, 100 count (NDC 65483-0392-10) 300 mg, 100 count (NDC 65483-0393-10) Reason for the Shortage Major, Sandoz, Teva, Prometheus cannot provide a reason for the shortage. Watson has labetaloll tablets on back order due to increased demand. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=840 Source: http://www.a ashp.org Vancomycin Hydrochloride Injection January 31, 2012 Products Affected - Description Vancomycin hydrochloride injection, Mylan Institutional 1 gram vial (NDC 10139-0501-12) - NDC discontinued Vancomycin hydrochloride injection, Akorn 500 mg vial (NDC 23360-0151-40) - discontinued 1 gram vial (NDC 23360-0152-50) - discontinued 5 gram vial (NDC 23360-0153-65) - discontinued Vancomycin hydrochloride injection, Hospira 750 mg vial (NDC 00409-6531-02) 1 gram Add-Vantage vials (NDC 00409-6535-01) 5 gram vial (NDC 00409-6509-01) 10 gram vial (NDC 00409-6510- -01) 10 gram Novaplus vials (NDC 00409-6510-49) Reason for the Shortage Hospira has vancomycin on shortage due to manufacturin ng delays. Akorn has sold their vancomycinn products to Pfizer and stopped distributing on April, 29, 2011. Mylan Institutional ( formerly Bioniche) has acquired multiple products from Generamedix, including vancomycin hydrochloride. Pfizer acquired multiple products from Akorn, includingg vancomycinn hydrochloride in early- May, 2011. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=132 Source: http://www.a ashp.org Sucralfate Oral Presentations January 31, 2012 Products Affected - Description Sucralfate tablets, Teva 1 gram, 500 count (NDC 00093-2210-05) 1 gram, 100 count (NDC 00093-2210-01) Sucralfate tablets, UDL 1 gram, 25 count unit-dose, robot-ready (NDC 51079-0871-19) 1 gram, 100 count unit-dose (NDC 51079-0871-20) Reason for the Shortage Teva, Watson and Axcan could not provide a reason for the shortage. UDL temporaroli discontinued their sucralfate products due to a raw materials shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=773 Source: http://www.a ashp.org 41
Page 1 and 2: February 2012 Drug Information Upda
Page 3 and 4: GENERIC DRUG NAME GENERIC APPROVAL
Page 5 and 6: CICLOPIROX/ TOPICAL PEDIPIROX-4 New
Page 7 and 8: [Posted 01/09/2012] ISSUE: Novartis
Page 9 and 10: Studies Article Link: http://www.fd
Page 11 and 12: the use of XARELTO® (rivaroxaban),
Page 13 and 14: acteria. The Food and Drug Administ
Page 15 and 16: Statins raise risk of Type 2 diabet
Page 17 and 18: The Million Women Study, a U.K. pro
Page 19 and 20: Azithromycin 250 mg tablets, 1 card
Page 21 and 22: RECALLING FIRM/MANUFACTURE Recallin
Page 23 and 24: Recalling Firm: Pfizer Us Pharmaceu
Page 25 and 26: 250 mg, 100 count (NDC 00591-3969-0
Page 27 and 28: Sandoz states the shortage is due t
Page 29 and 30: 5 mL ampule (NDC 10019-0033-72) 20
Page 31 and 32: Article Link: http://www.ashp.org/D
Page 33 and 34: Lidocaine 2% (with epinephrine 1:10
Page 35 and 36: Source: http://www.a ashp.org Halop
Page 37 and 38: ecome unavailable for an extended t
Page 39: American Regent resumed manufacturi
Page 43 and 44: Article link: http://www.ashp.org/D
Page 45 and 46: Bedford Laboratories has multiple p
Page 47 and 48: Thiothixene capsules, Mylan 2 mg ca
Page 49 and 50: 20 mL vials (NDC 10019-0905-03) - d
Page 51 and 52: 500 mg extended release, 500 count
Page 53 and 54: 1 mg/mL, 4 mL vial (NDC 25021-0781-
Page 55 and 56: West-Ward states the shortage is du
Page 57 and 58: 150 mL bottle (NDC 63304-0954-02) C

February 2012 Drug Update Information - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?